Truist Securities Assumes Sutro Biopharma at Buy, Announces Price Target of $50

Benzinga Newsdesk www.benzinga.com Positive 61.5%

Neg 0% Neu 0% Pos 61.5%

Truist Securities analyst Supawat Thongthip assumes Sutro Biopharma (NASDAQ:STRO) with a Buy rating and announces Price Target of $50.